Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
According to this study, over the next five years the Tyrosine Kinase JAK Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tyrosine Kinase JAK Inhibitors business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Tyrosine Kinase JAK Inhibitors market by product type, application, key manufacturers and key regions and countries.
This study considers the Tyrosine Kinase JAK Inhibitors value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Tofacitinib
Ruxolitinib
Baricitinib
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Tyrosine Kinase JAK Inhibitors consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Tyrosine Kinase JAK Inhibitors market by identifying its various subsegments.
Focuses on the key global Tyrosine Kinase JAK Inhibitors manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Tyrosine Kinase JAK Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Tyrosine Kinase JAK Inhibitors submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Summary:
Get latest Market Research Reports on Tyrosine Kinase JAK Inhibitors . Industry analysis & Market Report on Tyrosine Kinase JAK Inhibitors is a syndicated market report, published as Global Tyrosine Kinase JAK Inhibitors Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Tyrosine Kinase JAK Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.